Cassiopea SpA represents a strong commitment to innovation, integrity, and excellence. As a pharmaceutical company, Cassiopea SpA focuses on developing novel medical solutions to address unmet dermatological needs. With a forward-thinking approach, the company combines scientific expertise and cutting-edge research to create high-quality therapeutics. Cassiopea SpA's corporate philosophy centers around patient well-being, ethical conduct, and fulfilling the highest quality standards. By prioritizing patient satisfaction and providing effective treatments, Cassiopea SpA continues to make significant contributions to the healthcare industry.

Cassiopea SpA is primarily present in several countries and regions. The company has a significant presence in Europe, specifically in Italy where its headquarters are located. Additionally, Cassiopea SpA operates in various European countries, including Germany, Spain, France, and the United Kingdom, among others. It also has a presence in the United States, where it has established subsidiaries. Furthermore, Cassiopea SpA has expanded its operations into other regions such as Asia and Latin America. With its global reach, Cassiopea SpA maintains a strong presence in multiple countries and regions worldwide.

Cassiopea SpA has achieved several significant milestones as a leading company in the pharmaceutical industry. Over the years, the company has successfully developed innovative treatments for dermatological conditions. One notable achievement is the approval of their novel topical treatment, Winlevi, by the U.S. Food and Drug Administration (FDA). This milestone has positioned Cassiopea SpA as a key player in the global acne market. Additionally, the company has achieved success in advancing their pipeline of drug candidates, focusing on hair loss and genital warts therapies. Cassiopea SpA's dedication to research and development has propelled them towards continued growth and success in the healthcare sector.

Cassiopea SpA is a pharmaceutical company with a rich history and background. Founded in 2005, Cassiopea specializes in developing and commercializing innovative medical dermatology treatments. Based in Italy, the company focuses on dermatological and aesthetic conditions, aiming to improve patients' quality of life. Cassiopea is committed to delivering effective and safe treatments by combining thorough research, clinical trials, and regulatory expertise. With a strong portfolio of products, Cassiopea continues to expand its global presence and collaborations with key industry partners. This dedication to innovation and dermatological solutions has made Cassiopea SpA a trusted name in the pharmaceutical industry.

The main competitors of Cassiopea SpA in the market are Company X, Company Y, and Company Z.

Cassiopea SpA is primarily active in the pharmaceutical industry.

Cassiopea SpA operates as a specialty pharmaceutical company. The business model of Cassiopea SpA revolves around developing and delivering innovative medical solutions to address various dermatological and genital therapeutic areas. The company focuses on the research, development, and commercialization of pharmaceutical products primarily targeting diseases with limited treatment options or no solution at all. Cassiopea SpA strives to provide patients with effective, safe, and well-tolerated treatments to improve their quality of life. Through its dedicated team and extensive clinical research, Cassiopea SpA aims to meet the unmet medical needs of patients worldwide.

Cassiopea SpA KGV yra 10,04.

Cassiopea SpA KUV yra 9,28.

AlleAktien kokybės įvertis Cassiopea SpA yra 1/10.

tikėtina Cassiopea SpA pardavimai yra 39,40 mln. EUR.

tikėtina Cassiopea SpA pelnas yra 36,42 mln. EUR.

Cassiopea SpA is an Italian biopharmaceutical company that focuses on developing drugs for the treatment of skin and genital diseases. The company is listed on the Milan Stock Exchange and has a strong presence in Europe, the USA, and Australia. The three main product divisions of Cassiopea SpA are dermatology, urology, and gynecology. Within these divisions, there are a number of products and therapies developed and marketed by the company. In the dermatology division, the company has developed a promising acne therapy called Clascoterone, which is currently being tested in Phase III trials. This therapy aims to inhibit androgen receptors to reduce the growth of sebaceous glands and thus prevent the development of acne. Another promising development in the dermatology division is Winlevi, a topical medication for the treatment of rosacea that is near approval by the US Food and Drug Administration (FDA). In the urology division, Cassiopea focuses on developing drugs for the treatment of benign prostatic hyperplasia (BPH) and prostate cancer. The company has a number of promising therapies in the pipeline, including Enestro - a medication for the treatment of BPH, currently undergoing Phase II trials. Cassiopea's gynecology division focuses on developing drugs for the treatment of vulvovaginal diseases, such as lichen sclerosus. The company has developed a promising therapy called Clascoterone in this area. Cassiopea SpA follows an innovative business model based on the acquisition of promising technologies and therapies. The company is strongly focused on partnerships with leading biopharmaceutical companies to support its development and marketing activities. The company has an experienced management and development team that focuses on developing innovative technologies and therapies that meet the needs of patients and healthcare professionals. Cassiopea SpA has achieved strong growth numbers in recent years and is well positioned to continue growing by expanding its product lines and strengthening its position in the market. With its focus on developing drugs for the treatment of skin and genital diseases, the company has found a niche that offers unique opportunities for growth in a competitive environment.

Cassiopea SpA moka dividendą 0 EUR, kuris yra paskirstytas per išmokas per metus.

Dividenda šiuo metu negali būti apskaičiuota Cassiopea SpA arba įmonė dividendų nemoka.

Cassiopea SpA ISIN yra IT0005108359.

Cassiopea SpA WKN yra A14U64.

Cassiopea SpA akcijų simbolis yra SKIN.SW.

Per paskutinius 12 mėnesių Cassiopea SpA išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Cassiopea SpA tikėtina išmokės dividendus, kurie sudarys 0 EUR.

Cassiopea SpA šiuo metu yra dydžio dividendų grąža.

Cassiopea SpA moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Cassiopea SpA per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 EUR. Tai atitinka 0 % dividendų grąžos procentą.

Cassiopea SpA priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį Cassiopea SpA dividendą nuo 2024-12-23, kurio dydis yra 0 EUR, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-12-23.

Paskutinės dividendų išmokėjimas įvyko 2024-12-23.

2023 metais Cassiopea SpA išmokėjo 0 EUR dividendų.

Cassiopea SpA dividendai yra mokami EUR.